KR101539313B1 - 리스페리돈의 서방성 미소구체 조성물 - Google Patents

리스페리돈의 서방성 미소구체 조성물 Download PDF

Info

Publication number
KR101539313B1
KR101539313B1 KR1020137029953A KR20137029953A KR101539313B1 KR 101539313 B1 KR101539313 B1 KR 101539313B1 KR 1020137029953 A KR1020137029953 A KR 1020137029953A KR 20137029953 A KR20137029953 A KR 20137029953A KR 101539313 B1 KR101539313 B1 KR 101539313B1
Authority
KR
South Korea
Prior art keywords
lactide
glycolide
risperidone
capping
capping poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137029953A
Other languages
English (en)
Korean (ko)
Other versions
KR20140026481A (ko
Inventor
카오시앙 순
롱카이 리앙
퀼린 왕
웬얀 왕
왕후이 리우
유신 리
Original Assignee
산동 루예 파마슈티칼 컴파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47071591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101539313(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 산동 루예 파마슈티칼 컴파니 리미티드 filed Critical 산동 루예 파마슈티칼 컴파니 리미티드
Publication of KR20140026481A publication Critical patent/KR20140026481A/ko
Application granted granted Critical
Publication of KR101539313B1 publication Critical patent/KR101539313B1/ko
Assigned to 제네오라 파마 (스자좡) 컴퍼니 리미티드 reassignment 제네오라 파마 (스자좡) 컴퍼니 리미티드 권리의 전부이전등록 Assignors: 산동 루예 파마슈티칼 컴파니 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020137029953A 2011-04-25 2012-04-10 리스페리돈의 서방성 미소구체 조성물 Active KR101539313B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110102840 2011-04-25
CN201110102840.5 2011-04-25
PCT/CN2012/000473 WO2012146052A1 (en) 2011-04-25 2012-04-10 Risperidone sustained release microsphere composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157010621A Division KR101932207B1 (ko) 2011-04-25 2012-04-10 리스페리돈의 서방성 미소구체 조성물

Publications (2)

Publication Number Publication Date
KR20140026481A KR20140026481A (ko) 2014-03-05
KR101539313B1 true KR101539313B1 (ko) 2015-07-24

Family

ID=47071591

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137029953A Active KR101539313B1 (ko) 2011-04-25 2012-04-10 리스페리돈의 서방성 미소구체 조성물
KR1020157010621A Active KR101932207B1 (ko) 2011-04-25 2012-04-10 리스페리돈의 서방성 미소구체 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157010621A Active KR101932207B1 (ko) 2011-04-25 2012-04-10 리스페리돈의 서방성 미소구체 조성물

Country Status (14)

Country Link
US (5) US9446135B2 (https=)
EP (4) EP2701687B1 (https=)
JP (2) JP5728128B2 (https=)
KR (2) KR101539313B1 (https=)
CN (2) CN104127385B (https=)
AU (1) AU2012248038B2 (https=)
BR (1) BR112013027235B1 (https=)
CA (1) CA2832663C (https=)
ES (4) ES2855349T3 (https=)
HU (4) HUE046004T2 (https=)
PL (4) PL3566696T3 (https=)
PT (3) PT3199146T (https=)
RU (1) RU2586306C2 (https=)
WO (1) WO2012146052A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2855349T3 (es) 2011-04-25 2021-09-23 Shan Dong Luye Pharm Co Ltd Composición de risperidona de microesferas de liberación controlada
CN103990114B (zh) * 2014-05-06 2016-05-18 浙江圣兆药物科技股份有限公司 一种艾塞那肽缓释微球组合物
JP2016102093A (ja) * 2014-11-28 2016-06-02 ニプロ株式会社 塩基性の求核化合物を含有するマイクロカプセルの製造方法
JP6915540B2 (ja) * 2015-09-07 2021-08-04 ニプロ株式会社 リスペリドンを含有するマイクロカプセル、その製造方法および放出制御方法
CN105560192A (zh) * 2016-01-07 2016-05-11 万全万特制药江苏有限公司 一种棕榈酸帕利哌酮长效微球注射液的制备方法
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
CN106390102A (zh) * 2016-11-30 2017-02-15 郑州仁宏医药科技有限公司 一种治疗精神分裂症的西药组合物
CN106727589A (zh) * 2017-01-24 2017-05-31 广州帝奇医药技术有限公司 帕利哌酮及其衍生物的缓释组合物与该缓释组合物的制备方法
CN116270486A (zh) * 2017-01-24 2023-06-23 广州帝奇医药技术有限公司 水难溶或微溶性药物缓释组合物及其制备方法
CN106822042A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 一种利培酮缓释组合物及其制备方法
CN106822043A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 利培酮缓释组合物及其制备方法
CN106963746A (zh) * 2017-03-17 2017-07-21 广州帝奇医药技术有限公司 一种水难溶/微溶性药物缓释组合物
CN107349175A (zh) * 2017-06-06 2017-11-17 浙江理工大学 一种负载脂肪褐变剂的微针贴片及其制备方法
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
CN107213136B (zh) * 2017-06-07 2021-06-01 广州帝奇医药技术有限公司 一种长效缓释药物制剂及其制备方法
CN107412188A (zh) * 2017-09-06 2017-12-01 广州中医药大学 阿塞那平微球及其制备方法和其注射剂
CN108498456B (zh) * 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN108635339B (zh) * 2018-08-06 2021-07-06 深圳市泛谷药业股份有限公司 一种利培酮植入剂及其制备方法
GR1009870B (el) * 2019-07-09 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα ατυπο αντιψυχωσικο φαρμακο και μεθοδος παρασκευης αυτου
KR102908216B1 (ko) * 2019-12-31 2026-01-06 광저우 디치 파마슈티컬스 컴퍼니 리미티드 3차 아민 약학 조성물 및 이의 산업화 배치 제조 방법
WO2022270956A1 (ko) * 2021-06-23 2022-12-29 주식회사 펩트론 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
CN115006354A (zh) * 2022-06-16 2022-09-06 北京阳光诺和药物研究股份有限公司 一种利培酮-共混plga缓释微球及其制备方法
AU2023352588A1 (en) * 2022-09-26 2025-04-03 The Methodist Hospital Microparticle formulations for intravenous therapy and methods for their manufacture and use
CN118831056A (zh) * 2023-04-11 2024-10-25 珠海市华海康医药科技有限责任公司 一种注射用非奈利酮缓释微球及其制备方法
CN119606887A (zh) * 2023-11-09 2025-03-14 武汉人福创新药物研发中心有限公司 一种药物缓释微球组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101653422A (zh) * 2008-08-20 2010-02-24 山东绿叶制药有限公司 利培酮缓释微球、其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
ATE418323T1 (de) * 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
WO2004094415A1 (en) 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
EP1742616B1 (en) * 2004-04-30 2014-10-01 Abraxis BioScience, LLC Sustained-release microspheres and methods of making and using same
DE602005010812D1 (de) * 2004-11-22 2008-12-18 Hisamitsu Pharmaceutical Co Transdermales Pflaster enthaltend einen schmelzpunktsenkenden Hilfsstoff
CA2631811C (en) 2005-12-22 2017-06-20 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
CN101292960B (zh) 2006-04-29 2011-02-09 中国人民解放军军事医学科学院毒物药物研究所 含利培酮的缓释微球及其制备方法
AR066677A1 (es) 2007-05-24 2009-09-02 Novartis Ag Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.
EP2152315B1 (en) * 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
CN101584652B (zh) 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
ES2855349T3 (es) 2011-04-25 2021-09-23 Shan Dong Luye Pharm Co Ltd Composición de risperidona de microesferas de liberación controlada

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101653422A (zh) * 2008-08-20 2010-02-24 山东绿叶制药有限公司 利培酮缓释微球、其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
China Pharmacist 2009, vol. 12, no. 12, pp. 1713-1715 *

Also Published As

Publication number Publication date
PL2701687T3 (pl) 2017-03-31
US20170056407A1 (en) 2017-03-02
CN104127385B (zh) 2017-08-04
PT3566696T (pt) 2021-01-11
PL3199146T3 (pl) 2020-03-31
CA2832663A1 (en) 2012-11-01
US9446135B2 (en) 2016-09-20
US9532991B2 (en) 2017-01-03
CA2832663C (en) 2016-02-09
BR112013027235B1 (pt) 2021-11-16
US11110094B2 (en) 2021-09-07
EP3566696B1 (en) 2020-10-07
AU2012248038B2 (en) 2015-11-12
RU2013147949A (ru) 2015-05-27
HUE052864T2 (hu) 2021-05-28
BR112013027235A2 (pt) 2016-12-27
EP3772354B1 (en) 2023-11-01
US20190022098A1 (en) 2019-01-24
CN103338752B (zh) 2014-10-29
CN104127385A (zh) 2014-11-05
ES2607497T3 (es) 2017-03-31
EP2701687A1 (en) 2014-03-05
US10406161B2 (en) 2019-09-10
EP2701687B1 (en) 2016-09-21
KR20140026481A (ko) 2014-03-05
PL3566696T3 (pl) 2021-04-19
EP3566696A1 (en) 2019-11-13
US10098882B2 (en) 2018-10-16
EP3199146B1 (en) 2019-07-17
PT2701687T (pt) 2016-12-20
AU2012248038A1 (en) 2013-10-24
KR101932207B1 (ko) 2018-12-24
JP2015143259A (ja) 2015-08-06
JP2014512396A (ja) 2014-05-22
RU2586306C2 (ru) 2016-06-10
US20160331752A1 (en) 2016-11-17
ES2855349T3 (es) 2021-09-23
ES2749864T3 (es) 2020-03-24
CN103338752A (zh) 2013-10-02
US20190343840A1 (en) 2019-11-14
JP6072121B2 (ja) 2017-02-01
HK1185560A1 (en) 2014-02-21
EP3772354A1 (en) 2021-02-10
HUE046004T2 (hu) 2020-01-28
HUE032310T2 (hu) 2017-09-28
HUE066287T2 (hu) 2024-07-28
EP3199146A1 (en) 2017-08-02
JP5728128B2 (ja) 2015-06-03
EP2701687A4 (en) 2014-12-17
PL3772354T3 (pl) 2024-04-02
KR20150050598A (ko) 2015-05-08
WO2012146052A1 (en) 2012-11-01
ES2968917T3 (es) 2024-05-14
US20140050799A1 (en) 2014-02-20
PT3199146T (pt) 2019-10-25
EP3772354C0 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
KR101539313B1 (ko) 리스페리돈의 서방성 미소구체 조성물
JP5936705B2 (ja) 高融点疎水性化合物のバイオアベイラビリティが向上した薬学的組成物
KR20100017109A (ko) 지프라시돈 제제
EP4606371A1 (en) Lumateperone pharmaceutical composition, and long-acting microsphere sustained-release formulation and preparation method therefor
CN117530933A (zh) 一种吡仑帕奈长效缓释微球、制备方法及缓释注射剂
WO2023116517A1 (zh) 一种可平稳释放的持续性递送制剂及其制备方法
HK1185560B (en) Risperidone sustained release microsphere composition
CN120227341A (zh) 一种无延滞期的利培酮缓释微球及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20190625

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11